There is no specific test which can identify IBM in an individual, however, a combination of tests such as Full blood count, Calcium and Phosphate, Creatine Kinase, Erythrocyte Sedimentation Rate and so on will be a good indicator of whether the disorder has set in or not. There are however a number of therapies which have helped in slowing down IBM. This however is something, which is not found to be true across the board for all individuals, and results tend to vary. As such, clinical trials are still ongoing by numerous companies but nothing has been confirmed as of yet.
In terms of which regions are affected the most by this, North America and Europe are affected the most as on date. A number of reasons could be responsible for this some of which include the lifestyle being led as well as the climatic conditions where the cold could aid the early onset of this disorder. It is also for this reason that there is a high demand for numerous therapies in these regions for IBM.
The Inclusion body myositis Market can be segmented on the basis of structural feature as
Cytoplasmic Vacuolation, Inflammatory Infiltrate and Tubo-Filamentous
In terms of test type, the Inclusion body myositis Market has been segmented across the following
Full blood count, Calcium and Phosphate, Creatine Kinase, Erythrocyte Sedimentation Rate, and Fasting Glucose, Nerve conduction, Electromyography, Muscle Biopsy and Electron Microscopy
The market has been segmented based on the following geographies
North America, South America, APAC, Europe, Middle East and Africa
Following are just a few of the companies that are operating in the Inclusion body myositis Market.
Gradalis, Inc, New Zealand Pharmaceuticals Ltd, Nobelpharma Co and Novartis AG.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Inclusion body myositis– Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Inclusion body myositis– Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Inclusion body myositis Market
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Inclusion body myositis Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Inclusion body myositis Market– By Structural Feature:
6.1. Cytoplasmic Vacuolation
6.2. Inflammatory Infiltrate
7. Inclusion body myositis Market– By Test Type:
7.1. Full blood count
7.2. Calcium and Phosphate
7.3. Creatine Kinase
7.4. Erythrocyte Sedimentation Rate
7.5. Fasting Glucose
7.6. Nerve conduction
7.8. Muscle Biopsy
7.9. Electron Microscopy
8. Inclusion body myositis Market– By Geography:
8.2. Global Study
8.3.1. North America
9. Inclusion body myositis Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
10.1. Gradalis, Inc.
10.2. New Zealand Pharmaceuticals Ltd.
10.3. Nobelpharma Co
10.4. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights